Skip to content
The lessons of COVID-19 were unequivocal: Pandemic preparedness is key to national security. According to a national poll conducted by the Biotechnology Innovation Organization […]
Voters want better pandemic preparedness Read More »
The impact of drug price controls on innovation, market distortions caused by pharmacy benefit managers (PBMs), and the importance of accelerated approval came up
House 2024 health budget hearings touch on price controls and PBMs Read More »
The Council of State Bioscience Associations (CSBA), a coalition of state-based bioscience trade associations convened by the Biotechnology Innovation Organization (BIO), joined forces in
CSBA hits Capitol Hill for face time with lawmakers Read More »
Legislation that has been reintroduced in the Senate and has the support of the Biotechnology Innovation Organization (BIO) is set to enhance research, an
R&D in biotech gets a boost with reintroduced bill Read More »
The Department of Health and Human Services (HHS) and Department of Commerce (DOC) will investigate using Bayh-Dole march-in rights as a way to control
HHS investigating using Bayh-Dole march-in rights for price controls Read More »
The Senate Commerce Committee approved legislation yesterday which prohibits pharmacy benefit managers (PBMs) from pocketing the rebates they collect from drug makers. The bill
PBM Transparency Act now heads to full Senate Read More »
Government policy impacting biotech—including drug price controls, pharmacy benefit managers (PBMs), accelerated approval, and support for new antibiotics—received a public airing this week when
As Moderna CEO Stéphane Bancel heads to Capitol Hill to testify before the Health, Education, Labor, and Pensions (HELP) Committee, experts are watching to
To protect innovation, we need to protect Bayh-Dole, says one expert Read More »
On Wednesday, Moderna’s CEO will testify before the Senate Health, Education, Labor, and Pensions (HELP) Committee in a hearing with a misleading title, “Taxpayers
4 questions with Moderna President Stephen Hoge Read More »
While animal activists oppose animal testing on moral grounds, the biotech industry knows that alternative technology can provide more accurate and less expensive screening
Biotech wants to reduce animal testing and FDA is now tasked with helping Read More »
